Harada Kazuaki - Department of Gastroenterology and Hepatology, Hokkaido University Hospital

基本信息

浏览量：31

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 115 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Safety and Efficacy of Conversion Therapy for Metastatic Esophageal Cancer: Exploratory Analysis of JCOG1314

Satoru Matsuda,Hirofumi Kawakubo,Takahiro Tsushima,Shuichi Hironaka,Yasuhiro Tsubosa,Katsuyuki Sakanaka,Junya Oguma,Shigenori Kadowaki,Shigeru Tsunoda, Hiroki Hara,Kazuo Koyanagi,Toshifumi Yamaguchi,Kazuaki Harada,Masanobu Takahashi,Keiko Minashi, Eishi Baba,Keita Sasaki, Ryunosuke Machida,Hiroya Takeuchi

Journal of Clinical Oncologyno. 4_suppl (2025): 401-401

引用0浏览0引用

Results of a Phase 2 Trial of Ramucirumab Plus Docetaxel As Second-Line Treatment for Patients with Advanced Gastric Cancer (HGCSG 1903)

Kentaro Sawada,Yasuyuki Kawamoto,Kazuaki Harada,Takayuki Ando,Susumu Sogabe,Yoshimitsu Kobayashi,Masayoshi Dazai,Michio Nakamura,Kazuteru Hatanaka,Atsushi Ishiguro,Atsushi Sato,Shintaro Nakano,Yoshiaki Shindo,Ayumu Hosokawa,Ken Ito,Ayumu Yoshikawa, Kayoko Iuchi, Isao Yokota,Satoshi Yuki,Yoshito Komatsu

Journal of Clinical Oncologyno. 4_suppl (2025): 447-447

引用0浏览0引用

A Multicenter, Prospective Phase II Trial of Second-Line Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer Refractory to Anti-Egfr Agents (HGCSG1801): Updated Analyses

Hiroshi Nakatsumi,Kazuaki Harada,Satoshi Yuki,Atsushi Ishiguro,Kentaro Sawada,Susumu Sogabe,Takayuki Ando,Yusuke Sasaki,Ayumu Yoshikawa,Michio Nakamura,Masayoshi Dazai,Miki Tateyama,Osamu Muto,Masahito Kotaka, Tamotsu Sagawa,Tetsuhito Muranaka,Kazuteru Hatanaka, Ryo Takagi,Yuh Sakata,Yoshito Komatsu

Journal of Clinical Oncologyno. 4_suppl (2025): 147-147

引用0浏览0引用

Subcutaneous Adipose Tissue Radiodensity As a Predictor of Poor Prognosis in Advanced Biliary Tract Cancer

Ryo Sugiura,Yasuyuki Kawamoto,Masaki Kuwatani,Kazumichi Kawakubo,Kazuaki Harada,Masatsugu Ohara,Hiroki Yonemura,Shunichiro Nozawa,Naoya Sakamoto

JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2025)

引用0浏览0WOS引用

BAYONET Trial: Staged Combination with Encorafenib, Binimetinib, Plus Cetuximab Following Encorafenib Plus Cetuximab for BRAF V600E-mutant Metastatic Colorectal Cancer

Y. Matsubara,H. Bando,D. Kotani,Y. Kagawa,K. Harada,H. Osumi,N. Izawa,T. Kawakami,S. Boku, T. Matsumoto,M. Wakabayashi,T. Yoshino

ESMO Gastrointestinal Oncology (2024): 100066

引用0浏览0引用

Perioperative Chemotherapy with Nivolumab for HER2-negative Locally Advanced Gastric Cancer: a Case Series

Yuta Toji,Shintaro Takeuchi,Yuma Ebihara,Yo Kurashima,Kazuaki Harada,Mariko Hayashi,Hirotake Abe,Hideyuki Wada,Satoko Yorinaga,Toshiaki Shichinohe,Utano Tomaru,Yoshito Komatsu,Satoshi Hirano

Surgical Case Reportsno. 1 (2024): 1-9

引用0浏览0WOS引用

79P the Role of Regorafenib for Metastatic Colorectal Cancer in the New Era of Later-Line Treatment: Results of the OSERO Study

T. Matsumoto,T. Kawakami,T. Hamano,T. Masuishi,A. Chida,S. Mitani,A. Ishiguro,T. Ando,K. Sawada,K. Harada, N. Takahashi,S. Boku,T. Kashiwada,T. Esaki,M. Yagisawa, K. Sugiyama, K. Yamamoto,S. Yuki,K. Yamazaki,E. Oki

Annals of Oncology (2024): S1434-S1435

引用0浏览0引用

521P Risk Factors for Early Discontinuation of Anamorelin Hydrochloride in Patients with Cancer Cachexia: A Multicenter, Retrospective Cohort Study (HGCSG2201)

K. Harada,S. Kajiura,K. Sawada,K. Hatanaka,A. Sato, K. Ito, H. Tamura,A. Doi,T. Ando, M. Nakamura,H. Nakatsumi,T. Muranaka,S. Sogabe, T. Ishii,S. Nakano,M. Dazai, Y. Sasaki,Y. Kawamoto,S. Yuki,Y. Komatsu

Annals of Oncology (2024): S207-S208

引用0浏览0引用

Risk Factors for Early Discontinuation of Anamorelin Hydrochloride in Patients with Cancer Cachexia: A Multicenter, Retrospective Cohort Study (HGCSG2201)

K. Harada,S. Kajiura,K. Sawada,K. Hatanaka,A. Sato,K. Ito, H. Tamura,A. Doi,T. Ando,M. Nakamura,H. Nakatsumi,T. Muranaka,S. Sogabe, T. Ishii,S. Nakano,M. Dazai,Y. Sasaki,Y. Kawamoto,S. Yuki,Y. Komatsu

ANNALS OF ONCOLOGY (2024): S207-S208

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn